These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 15170907)

  • 21. Update on psoriatic arthritis.
    Michet CJ
    Int J Dermatol; 2004 Jul; 43(7):479-81. PubMed ID: 15230883
    [No Abstract]   [Full Text] [Related]  

  • 22. Should tuberculin skin test be positive to give latent tuberculosis treatment before tumor necrosis factor-alpha inhibitors in selected patients in developing countries?
    Abud-Mendoza C; Martínez-Martínez MU; DE Jesús Macías-Mendoza J; Magaña-Aquino M
    J Rheumatol; 2010 Mar; 37(3):672-3; author reply 673. PubMed ID: 20197567
    [No Abstract]   [Full Text] [Related]  

  • 23. Immunogenicity of TNF alpha inhibitors in rheumatology: many questions, enough answers?
    Wendling D; Verhoeven F; Guillot X; Prati C
    Expert Opin Drug Saf; 2017 Jan; 16(1):1-3. PubMed ID: 27737601
    [No Abstract]   [Full Text] [Related]  

  • 24. Anti-adalimumab antibodies in paediatric rheumatology patients: a pilot experience.
    Murias S; Alcobendas R; Pascual-Salcedo D; Remesal A; Peralta J; Merino R
    Rheumatology (Oxford); 2014 Nov; 53(11):2124-6. PubMed ID: 25102859
    [No Abstract]   [Full Text] [Related]  

  • 25. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.
    Mohan N; Edwards ET; Cupps TR; Slifman N; Lee JH; Siegel JN; Braun MM
    J Rheumatol; 2004 Oct; 31(10):1955-8. PubMed ID: 15468359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in targeted therapies XIII.
    Breedveld FC; Kalden JR; Smolen JS
    Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i1. PubMed ID: 22460135
    [No Abstract]   [Full Text] [Related]  

  • 27. Recommended screening strategy for preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India - followup report.
    Malaviya AN; Kapoor S; Garg S; Rawat R
    J Rheumatol; 2010 Jan; 37(1):209. PubMed ID: 20040648
    [No Abstract]   [Full Text] [Related]  

  • 28. mAbs in nonlupus autoimmune rheumatic disease.
    Whelan BR; Isenberg DA
    Curr Opin Hematol; 2009 Jul; 16(4):280-4. PubMed ID: 19444098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
    Guillevin L; Mouthon L
    J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
    [No Abstract]   [Full Text] [Related]  

  • 30. Mechanisms of action of tumor necrosis factor antagonist and granulomatous infections.
    Beenhouwer D; Wallis R; Broder M; Furst DE
    J Rheumatol; 2004 Oct; 31(10):1888-92. PubMed ID: 15487038
    [No Abstract]   [Full Text] [Related]  

  • 31. Improved insulin sensitivity by anti-TNFalpha antibody treatment in patients with rheumatic diseases.
    Huvers FC; Popa C; Netea MG; van den Hoogen FH; Tack CJ
    Ann Rheum Dis; 2007 Apr; 66(4):558-9. PubMed ID: 17360784
    [No Abstract]   [Full Text] [Related]  

  • 32. The 2005 International Symposium on Advances in Targeted Therapies: what have we learned in the 2000s and where are we going?
    Maini RN
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4():iv106-8. PubMed ID: 16239377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Do DMARDs contibute to impaired healing after surgery? Should they be discontinued before surgery?].
    Glück T; Müller-Ladner U
    Dtsch Med Wochenschr; 2007 Sep; 132(37):1901-4. PubMed ID: 17823884
    [No Abstract]   [Full Text] [Related]  

  • 34. Mechanism of action of tumor necrosis factor antagonists. Proceedings of the Canadian expert roundtable meeting, Banff, Canada, November 28-30, 2003.
    J Rheumatol Suppl; 2005 Mar; 74():1-47. PubMed ID: 15742456
    [No Abstract]   [Full Text] [Related]  

  • 35. Setting the research agenda for future clinical trials on the use of biologics in rheumatology.
    Silman A; Rudkin S; Walley T
    Rheumatology (Oxford); 2011 Aug; 50(8):1356-7. PubMed ID: 21118870
    [No Abstract]   [Full Text] [Related]  

  • 36. Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk.
    Khasnis AA; Calabrese LH
    Semin Arthritis Rheum; 2010 Oct; 40(2):147-63. PubMed ID: 19914686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis.
    Kavanaugh A; Cohen S; Cush JJ
    J Rheumatol; 2004 Oct; 31(10):1881-4. PubMed ID: 15468347
    [No Abstract]   [Full Text] [Related]  

  • 38. Immunogenicity of anti-tumour necrosis factor drugs in rheumatic diseases.
    Spinelli FR; Valesini G
    Clin Exp Rheumatol; 2013; 31(6):954-63. PubMed ID: 23981925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of anti-tumor necrosis factor agents in rheumatic potential carriers of occult hepatitis B virus.
    Giannitti C; Sebastiani GD; Manganelli S; Galeazzi M
    J Rheumatol; 2011 Apr; 38(4):780-1. PubMed ID: 21459960
    [No Abstract]   [Full Text] [Related]  

  • 40. Biologic agents in the treatment of rheumatic diseases with chronic viral infection. Where are we?
    Wendling D; Di Martino V; Herbein G
    J Rheumatol; 2009 Jun; 36(6):1107-8. PubMed ID: 19509089
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.